An outpatient, randomised, double-blind, placebo controlled, parallel group exploratory study to evaluate safety, tolerability and efficacy of GW679769 [casopitant] in patients with fibromyalgia syndrome comorbid with depression.
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2015
At a glance
- Drugs Casopitant (Primary)
- Indications Depression; Fibromyalgia
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 14 Oct 2008 Trial phase changed from I/II to II as reported by ClinicalTrials.gov.
- 15 Sep 2006 New trial record.